MDC Stock Overview
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Medlab Clinical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$6.60 |
| 52 Week High | AU$14.94 |
| 52 Week Low | AU$6.45 |
| Beta | 1.1 |
| 1 Month Change | 0% |
| 3 Month Change | -4.21% |
| 1 Year Change | -43.59% |
| 3 Year Change | -79.05% |
| 5 Year Change | -91.85% |
| Change since IPO | -78.00% |
Recent News & Updates
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30
Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22Shareholder Returns
| MDC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 2.4% |
| 1Y | -43.6% | 3.6% | 7.7% |
Return vs Industry: MDC underperformed the Australian Biotechs industry which returned 11.4% over the past year.
Return vs Market: MDC underperformed the Australian Market which returned -1.5% over the past year.
Price Volatility
| MDC volatility | |
|---|---|
| MDC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: MDC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MDC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Sean Hall | www.medlab.co |
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery.
Medlab Clinical Limited Fundamentals Summary
| MDC fundamental statistics | |
|---|---|
| Market cap | AU$15.07m |
| Earnings (TTM) | -AU$8.32m |
| Revenue (TTM) | AU$1.54m |
9.8x
P/S Ratio-1.8x
P/E RatioIs MDC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDC income statement (TTM) | |
|---|---|
| Revenue | AU$1.54m |
| Cost of Revenue | AU$336.29k |
| Gross Profit | AU$1.20m |
| Other Expenses | AU$9.52m |
| Earnings | -AU$8.32m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.64 |
| Gross Margin | 78.11% |
| Net Profit Margin | -541.67% |
| Debt/Equity Ratio | 0% |
How did MDC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/22 00:33 |
| End of Day Share Price | 2023/02/22 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medlab Clinical Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Fraser | APP Securities Pty Ltd. |
| Jonas Peciulis | Edison Investment Research |
| Iain Wilkie | Morgans Financial Limited |